Trial Profile

Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Datopotamab deruxtecan (Primary) ; Pembrolizumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms TROPION-Lung02
Sponsors Daiichi Sankyo Inc

01 Jun 2025 According to a Daiichi Sankyo Company Media Release, data from this study presented at the 2025 American Society of Clinical Oncology (#ASCO25) Annual Meeting.
01 Jun 2025 Results presented in a Daiichi Sankyo Company Media Release.
13 May 2025 According to a Merck Sharp & Dohme media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30-June 3).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com